Self-Selected Versus Physiotherapist-Prescribed Resistance Training Program In People With Chronic Low Back Pain (MyBackExercise)
Efficacy of a Self-Selected Resistance Training Program Compared With a Physiotherapist-Prescribed Resistance Training Program in People With Chronic Low Back Pain (MyBack Exercise): A Randomized Control Pilot Study
Chronic low back pain is a public health issue affecting over 20% of the Spanish population, causing disability, reduced quality of life, and work absenteeism. Over the past decades, the benefits of physical exercise for improving symptoms in patients with chronic low back pain have been studied. Exercise has also been shown to improve quality of life, general health, self-efficacy, and fear of pain, regardless of pathology. Research on the effect of physical exercise in chronic low back pain patients has shown promising results. Therefore, the therapeutic exercise program proposed in this study may help participants adopt healthy habits that positively impact their quality of life.
This will be a clinical trial in patients with chronic low back pain. The main purpose of the study is to evaluate the efficacy of a self-selected resistance training program versus physiotherapist-prescribed exercises in improving pain intensity and disability in adults with chronic low back pain. Secondary objectives include evaluating differences between the two groups after 12 weeks in treatment satisfaction, degree of compliance, kinesiophobia, self-efficacy, muscle endurance, and lumbar electromyographic activity.
If you agree to participate, a member of the research team experienced in exercise programs for chronic low back pain will instruct you on how to perform the program. The follow-up study will include 34 participants randomly assigned to two groups: one group performing self-selected resistance exercises, and one group performing physiotherapist-prescribed exercises. The study will last 12 weeks, assessing your condition at the start and end of the study. You will complete questionnaires on pain intensity (Numerical Pain Rating Scale, NPRS), disability (Oswestry Disability Index, ODI), treatment satisfaction (CRES-4), adherence to treatment, kinesiophobia (TSK-11), self-efficacy (Pain Self-Efficacy Questionnaire, PSEQ), muscle endurance (Biering-Sørensen test), and surface electromyographic activity of the erector spinae (longissimus) muscle (sEMG-ESL) using the mDurance® device.
POTENTIAL BENEFITS AND RISKS OF PARTICIPATION Expected direct benefits of participation may include improvements in pain intensity, disability, treatment satisfaction, adherence to therapeutic exercise, kinesiophobia, self-efficacy, muscle endurance, and electromyographic activity.
However, it is possible that you may not experience any personal benefit. The information obtained will contribute to scientific knowledge about CLBP and may help others in the future.
ALTERNATIVE TREATMENTS Chronic low back pain is a pathological entity with extensive study, which can present different conservative therapeutic options, such as psychological therapy, regular physical exercise and the adoption of healthy habits.
COMPENSATION Participation in this study will not incur any costs for you. OTHER RELEVANT INFORMATION Any new information discovered during your participation that may affect your willingness to participate in the study will be communicated to you by your doctor as soon as possible.
If you decide to withdraw your consent to participate in this study, no new data will be added to the database, and if samples have already been collected, you may request the destruction of all previously obtained, identifiable samples to avoid further analysis.
You should also be aware that you may be excluded from the study if the sponsor or researchers deem it necessary, either for safety reasons or because they believe you are not complying with the established procedures.
In either case, you will receive a clear explanation of the reason for your withdrawal from the study. The sponsor may suspend the study for any of the reasons stipulated in current legislation.
By signing the attached consent form, you agree to comply with the study procedures explained to you. When your participation is over, you will receive the best available treatment that your doctor considers most appropriate for your condition.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Luis González Gómez, PT, MSc
- Telefoonnummer: +34 637958168
- E-mail: luis.gonzalezgomez@alum.uca.es
Studie Contact Back-up
- Naam: Francisco José García Bustos, PT
- Telefoonnummer: +34 654623204
- E-mail: garcia_frabus@gva.es
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria
a) Male and female participants aged 18-65 years b) Low back pain, with or without referred pain to the lower limb, persisting for ≥12 weeks c) Not currently engaged in a regular structured exercise programme d) Sufficient cognitive and communication abilities to complete the assessment scales and participate in the study intervention Exclusion Criteria
- Lumbar radiculopathy or radicular pain syndrome, defined by clinical signs of nerve root involvement (e.g., dermatomal pain, neurological deficits, or positive neurodynamic tests)
- Serious spinal or non-spinal pathology explaining low back pain, identified through clinical assessment (e.g., malignancy, vertebral fracture, spinal infection, cauda equina syndrome, inflammatory spinal disease, vascular, visceral or other serious causes).
- Medical contraindications to exercise, as determined by the treating physician The presence of lumbar degenerative imaging findings (e.g., degenerative disc disease, lumbar spondylosis, facet joint osteoarthritis, or Modic changes) will not constitute an exclusion criterion, provided that the clinical presentation is consistent with chronic low back pain.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm experimental
|
The experimental group will follow a programme with different RT options. This proposal will be displayed on a board with detailed images of the exercises in the treatment centre. Each patient will individually choose six exercises daily; two for each body part (upper limb; lower limb; trunk). Each patient's individual choice of exercises will be recorded using checklists. Under no circumstances will the physiotherapist guidance take precedence; the clinician will refrain from expressing their preferences and beliefs regarding the selected-exercise. The patient will have the option to repeat or vary the exercises throughout the training programme, if they so decide. For both groups, the treatment materials will include variable-resistance elastic bands, adjustable dumbbells, chairs, and a roman chair. Therapeutic supervision will be provided face-to-face for all study participants by three experimented physiotherapists from the research group. |
|
Actieve vergelijker: Arm control
|
The control group will carry out a physiotherapist-prescribed RT programme.
Participants in this group will not be able to choose their exercises and will perform six exercises: push-ups, row, squat, deadlift, abdominal crunch and back extension.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pain-related distribution and intensity
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
|
Pain distribution will be evaluated using a 45-region body map to identify painful body areas.
Pain intensity will be measured separately for low back pain and leg pain using the Numerical Pain Rating Scale (NPRS), a continuous measure ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.
|
From enrollment to the end of treatment at 12 weeks
|
|
Disability
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
|
Disability will be measured as a discrete quantitative variable using the Oswestry Disability Index (ODI), with a total score ranging from 0 to 50 points, reflecting the degree of functional limitation associated with CLBP.
|
From enrollment to the end of treatment at 12 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment satisfaction
Tijdsspanne: From T1 (4 weeks) to the end of treatment at 12 weeks
|
Treatment satisfaction will be evaluated as an ordinal quantitative variable using the Treatment Satisfaction Scale (CRES-4), with total scores ranging from 4 to 20 points, where higher scores indicate greater satisfaction with the received treatment.
|
From T1 (4 weeks) to the end of treatment at 12 weeks
|
|
Degree of compliance
Tijdsspanne: From T1 (4 weeks) to the end of treatment at 12 weeks
|
Degree of compliance with treatment will be assessed as an ordinal quantitative variable based on the percentage of completed sessions out of the total 24 scheduled sessions.
|
From T1 (4 weeks) to the end of treatment at 12 weeks
|
|
Kinesiophobia
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
|
Kinesiophobia will be measured as a continuous quantitative variable using the Tampa Scale for Kinesiophobia (TSK-11), with scores ranging from 11 to 44 points, where higher scores reflect greater fear of movement.
|
From enrollment to the end of treatment at 12 weeks
|
|
Self-efficacy
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
|
Self-efficacy will be assessed as an ordinal quantitative variable using the Pain Self-Efficacy Questionnaire (PSEQ), with scores ranging from 0 to 60 points, indicating the individual's confidence in performing daily activities despite pain.
|
From enrollment to the end of treatment at 12 weeks
|
|
Muscle endurance
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
|
Muscle endurance will be evaluated as a continuous quantitative variable using the Biering-Sørensen test, with performance time ranging from 0 to 240 seconds.
|
From enrollment to the end of treatment at 12 weeks
|
|
Surface electromyographic activity of the erector spinae (longissimus) muscle (sEMG-ESL)
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
|
The activity of the erector spinae (longissimus) muscle will be assessed as a continuous quantitative variable using surface electromyography, expressed in microvolts (μV), and quantified through the root mean square (RMS) using the mDurance® device.
|
From enrollment to the end of treatment at 12 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: José A. Moral Muñoz, PT, PhD, University of Cadiz (Spain)
- Studie directeur: Álvaro José Rodríguez Domínguez,, PT, PhD, Centro Universitario San Isidoro, affiliated with Pablo de Olavide University (Spain)
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026-0301-1
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
To ensure the privacy and confidentiality of participants, all clinical data collected in the study will be anonymized prior to analysis. Names, identification numbers, and specific dates will be removed, and any indirect identifiers that could allow subject identification will be grouped and coded. The anonymization process will be conducted in accordance with current ethical and regulatory standards, ensuring that the data remain valid for statistical analysis without compromising individual privacy.
All physical documents will be stored in locked filing cabinets within a secure area with restricted access. Electronic data will be entered into a secure, password-protected database specifically designed for the study. Access to the data will be limited to research team members listed in the study protocol.
Data supporting the findings of this study will not be publicly available due to sensitivity but may be obtained from the corresponding author upon justified request. All data will
IPD-tijdsbestek voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .